79,683 Shares in ANI Pharmaceuticals, Inc. $ANIP Purchased by Jupiter Topco LLC

Jupiter Topco LLC purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 79,683 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,597,000.

Other large investors also recently bought and sold shares of the company. KBC Group NV purchased a new stake in ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. increased its holdings in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $48,000. Finally, State of Wyoming acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $50,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $72.83 on Monday. The company’s fifty day moving average price is $79.68 and its 200 day moving average price is $78.64. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The stock has a market capitalization of $1.67 billion, a P/E ratio of 15.70 and a beta of 0.44. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim lowered their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group cut their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.83.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the sale, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. The trade was a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the sale, the senior vice president owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 24,387 shares of company stock valued at $1,947,625. Corporate insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.